Skip to main content
Back
Watch Compare

SANGAMO THERAPEUTICS, INC

Data quality: 100%
SGMO
NASDAQ Manufacturing Chemicals
$0.27
▼ $0.00 (-0.25%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-22.69%

Growth

Revenue Growth (5Y)
-22.69%
Below sector avg (1.92%)
Revenue (1Y)-31.57%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-951.30%
Below sector avg (-54.47%)
ROIC-216.65%
Net Margin-310.81%
Op. Margin-306.53%

Safety

Debt / Equity
N/A
Current Ratio0.88
Interest CoverageN/A

Valuation

PE (TTM)
-0.92
Above sector avg (-1.50)
P/B Ratio18.03
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue declined -22.69% annually over 5 years
Negative free cash flow of -97.31 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 8.88%
Capital efficient — spends only 0.26% of revenue on capex

Price History

Financial Trends

Analyst Price Target

4 analysts
Buy
+1266.6%
upside to target
Current
$0.27
Consensus Target
$3.75
$1.00
Low
$10.00
High
Forecast
Forward EPS
$0.00
Est. Revenue
130.13 M

Earnings Surprises

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -$0.07 · Rev Est: 33.73 M
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -$0.14 -$0.08 -$0.11 -$0.07 — —
Estimate -$0.13 -$0.13 -$0.10 -$0.05 -$0.07 -$0.07
Surprise -7.69% +36.00% -6.46% -54.70% — —

Growth

Rev 5Y: -22.69% · Earnings 1Y: N/A
Revenue Growth (1Y) -31.57% Revenue Growth (3Y) -52.63%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -22.69% Earnings Growth (5Y) N/A

Profitability

ROE: -951.30% · Net Margin: -310.81%
Revenue (TTM) 39.55 M Net Income (TTM) -122.93 M
ROE -951.30% ROA -132.04%
Gross Margin N/A Operating Margin -306.53%
Net Margin -310.81% Free Cash Flow (TTM) -97.31 M
ROIC -216.65% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 0.88
Debt / Equity N/A Current Ratio 0.88
Interest Coverage N/A Asset Turnover 0.42
Working Capital -6.05 M Tangible Book Value 6.24 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0.92 · EV/EBITDA: N/A
P/E Ratio -0.92 Forward P/E N/A
P/B Ratio 18.03 P/S Ratio 2.85
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 0.87 Fwd Earnings Yield N/A
FCF Yield -86.45%
Market Cap 112.56 M Enterprise Value 82.94 M

Per Share

EPS: -0.44 · FCF/Share: -0.23
EPS (Diluted TTM) -0.44 Revenue / Share 0.10
FCF / Share -0.23 OCF / Share -0.23
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 79.16% · CapEx/Rev: 0.26%
CapEx / Revenue 0.26% FCF Conversion 79.16%
SBC-Adj. FCF -107.57 M Growth Momentum -8.88

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 39.55 M 57.80 M 176.23 M 111.30 M 110.70 M
Net Income -122.93 M -97.94 M -257.83 M -192.28 M -178.29 M
EPS (Diluted) -0.44 -0.49 -1.48 -1.25 -1.23
Gross Profit — — — — —
Operating Income -121.24 M -103.97 M -274.01 M -201.28 M -183.34 M
EBITDA — — — — —
R&D Expenses 112.67 M 111.52 M 234.06 M 249.90 M 230.82 M
SG&A Expenses — — — — —
D&A 3.96 M 5.11 M 15.07 M 12.11 M 9.44 M
Interest Expense — — — — —
Income Tax -568,000.0 -167,000.0 -5.07 M 429,000.0 306,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 59.75 M 101.64 M 165.32 M 562.51 M 721.92 M
Total Liabilities 74.01 M 78.87 M 82.43 M 267.55 M 346.58 M
Shareholders' Equity -14.27 M 22.77 M 82.89 M 294.96 M 375.34 M
Total Debt — — — — —
Cash & Equivalents 20.95 M 41.92 M 45.20 M 100.44 M 178.87 M
Current Assets 35.83 M 51.69 M 94.33 M 300.33 M 398.77 M
Current Liabilities 42.47 M 45.81 M 47.73 M 111.71 M 127.89 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -0.9 -1.5
P/B 18.0 1.6
ROE % -951.3 -54.5
Net Margin % -310.8 -41.5
Rev Growth 5Y % -22.7 1.9
D/E — 0.3

ETFs Holding This Stock
DLHAX DLHAX
0.02% weight
DLRHX DLRHX
0.02% weight
DLHIX DLHIX
0.02% weight